CNBX - Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies
TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids. The screening of the antitumor properties of cannabinoids on cancer cell lines produces data on groups of patients, while the primary biopsy samples provide us insights on the individual level and may better predict the clinical outcome and improve our preclinical development of proprietary antitumor compounds."
Watch a Video introduction to Cannabics' Lab: https://www.youtube.com/embed/mte263r7nFA
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. For example, we are using forward-looking statements when we discuss the belief that the initiation of this study is a quantum leap for the research on the biology of cancer and cannabinoids and that the screening of the antitumor properties of cannabinoids on cancer cell lines may better predict the clinical outcome and improve our preclinical development of proprietary antitumor compounds. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429
info@cannabics.com
http://www.cannabics.com
SOURCE Cannabics Pharmaceuticals Inc.